Compare Crispr Therapeutics AG (CRSP) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Robinhood Markets, Inc. — how do they compare? Crispr Therapeutics AG trades at $53.55 (market cap $4.88B), while Robinhood Markets, Inc. trades at $109.1 (market cap $96.21B). The key difference: Robinhood Markets, Inc. is far larger — about 19.7× Crispr Therapeutics AG's market cap, and Robinhood Markets, Inc. is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Robinhood Markets, Inc. for 75 Days on average.
| CRSP | HOOD | |
|---|---|---|
Market Cap | $4.88B | $96.21B |
Volume | 2,861,747 | 22,572,153 |
Sector | Health | Financials |
52-Week High | $74.92 | $152.46 |
52-Week Low | $44.34 | $65.16 |
Typical Hold Time | 77 Days | 75 Days |
Enterprise Value | $3.30B | $102.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
Robinhood (HOOD) trades at $109.02, down 0.45% on the day, with a bullish technical signal and strong support at $105. The company reported robust 2025 results with revenue of $4.47B and net income of $1.88B, though valuation ratios like a P/E of 47.35 remain elevated. Recent news highlights expansion into 24/7 stock trading and new product launches aimed at driving growth.
The outlook is positive with a consensus price target of $137.53, implying 26% upside, supported by analyst optimism and product innovation. Key risks include high valuation sensitivity, competitive pressures, and regulatory scrutiny over new offerings like leveraged crypto trading, which could impact investor sentiment and stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
